Lombard Medical Technologies Share Discussion Threads

[philo124] 20/11/2013 06:51

Interesting.

[nod] 20/11/2013 01:37

BOTHELL, Wash., Nov. 19, 2013 /PRNewswire via COMTEX/ -- BioLife Solutions, Inc. (otcqb:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has appointed a new chairman of the board and also a new director.Current board director Raymond Cohen was appointed non-executive Chairman of the Board, replacing Mike Rice, President & CEO, who remains in that role and on the board. Cohen is currently the Chairman of the Board of Lombard Medical Technologies, PLC, a UK public medical device company. He is also Chairman of the Board of JenaValve Technology, Inc., a privately held, Munich-based medical device company. Cohen is also a director of Spectrum Pharmaceuticals, Syncroness, Inc., and LoneStar Heart, Inc. He was most recently the Chief Executive Officer of Vessix Vascular, Inc., and led its November 2012 acquisition by Boston Scientific, a deal valued at up to $425 million.

[callumross] 18/11/2013 20:15

That's because many of LMT's trades are transacted and published through the ISDX platform, shorewalk.

[shorewalk] 18/11/2013 13:13

Don't know how many other trades aren't being reported - but my top up buy isn't, so suspect it is not alone. Would like company to report latest numbers on procedures as we should then start to move upwards.

[nod] 18/11/2013 10:22

That's an impressive list of speakers presenting on various Aorfix research.

[philo124] 18/11/2013 10:02

Canaccord 256p Buy reiteration.

[skinny] 18/11/2013 07:17

The Only FDA Approved Endovascular Stent Graft for Use in Challenging Abdominal Aortic Aneurysm Cases

London, UK and Irvine, CA, November 18, 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces a stand-alone symposium and program of presentations to mark the formal US launch of Aorfix™, the Company's flexible stent graft, at the 40th Annual VEITH Symposium, November 19-23, New York Hilton Midtown Hotel, Manhattan, New York City.

CEO of Lombard Medical Technologies, Simon Hubbert, commented:
"Published clinical data suggest that up to 30% of patients present with tortuous AAA anatomy. US physicians now have access to Aorfix, a highly effective, FDA approved treatment option for such cases. VEITH Symposium is one of the most important annual gatherings of vascular surgeons from around the world and the ideal venue to formally launch Aorfix in the US."

Aorfix was approved by the US FDA in February this year and includes a unique label indication for the treatment of patients with neck angulations up to and including 90 degrees. Lombard Medical will be hosting a launch stand-alone symposium, where leading physicians will present clinical data and provide their first-hand experience of Aorfix, on Thursday November 21, 12:00 noon to 1:00 PM.

Clinical discussions at the launch stand-alone symposium will be led by key investigators from the Pythagoras US clinical trial of Aorfix, including:

· Overall 1-year results of the Aorfix Pythagoras PMA Study - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial
· Anatomical angles and effect on Aorfix PMA Study results - Mahmoud B. Malas, M.D. Chief of Endovascular Surgery and Director of Vascular and Endovascular Clinical Research, Johns Hopkins Bayview Medical Center
· Gender and its impact on Aorfix PMA Study outcomes - William D. Jordan Jr., M.D. Professor of Vascular Surgery, University of Alabama School of Medicine
· Access techniques for tortuous anatomy - Jeffrey P. Carpenter, M.D. Chairman and Chief, Department of Surgery, Cooper University Health Care
· Clinical insights from the Aorfix PMA Study - Kim J. Hodgson, M.D. Professor and Chair, Division of Vascular Surgery, SIU School of Medicine

In addition, Lombard Medical will host a meeting and product demonstration for investors and analysts on November 20, 2:30 PM to 4:30 PM at the Hilton hotel, no new material financial or other information will be disclosed.

The following presentations highlighting Aorfix will also take place at this year's VEITH Symposium on Friday November 22:

· Advantages and Limitations of the Lombard Aorfix Endograft. Now FDA Approved in the US - Mark F. Fillinger, M.D. Director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard's PMA Trial
· Challenging Anatomy: Can Freedom from Adjunctive Fixation mean Freedom from Migration and Endoleak? - Prof. Brian R. Hopkinson, M.D., Emeritus Professor of Vascular Surgery, University of Nottingham; Consultant Vascular Surgeon, Queen's Medical Centre, Nottingham, United Kingdom


-Ends-

[skinny] 28/10/2013 07:07

USPTO Accepts Lombard's Request to Dismiss Inter Partes Review


London, UK, 28 October 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces that following its request, the US Patent and Trademark Office (USPTO) has granted the motion to dismiss the Inter Partes Review (IPR) regarding the validity of US patent No. 6,306,141 ('141 or "Jervis" patent).

The Company's request to withdraw the IPR was a condition of the non-exclusive licence granted to the Company by Medtronic, Inc. for Medtronic's '141 patent (previously announced on 17 October).

-Ends-

[nod] 18/10/2013 00:01

Yes, good point. Legal threat gave Medtronic significant leverage to take a slice of Aorfix. Years of legal action would have ruined LMT and held up sales in the USA. Now the claim has been dropped it clears the way for a bid from Medtronic and possible a n other.

[shorewalk] 17/10/2013 12:32

At least didn't get screwed over as badly as Aerotech. Medtronic will no doubt be the eventual owner of LMT and may get at a lower price as a consequence, but still at a substantial premium to todays share price Damaging a company whose product is as beneficial as this might not have reflected too well with medical profession and affected other areas of their business. Although Medtronic is so big they probably spend more on printer ink than the value of LMT. Part of dropping legal is they would be scrutinized if they bought shares or made a bid whilst in a wrangle IMHO

[skinny] 17/10/2013 12:05

Canaccord Genuity Buy 208.00 204.50 256.00 256.00 Reiterates

[nod] 17/10/2013 11:05

While this sort of legal blackmail and bullying is immoral it is increasingly the American way of dealing with competition and the rest of the world has to deal with this. It's an unbalanced world that keeps USA companies at the top. Fortunately the Chinese and other Asian regions can mostly ignore these legal threats and are able to move the world forward at a faster pace than would otherwise be possible.

[shorewalk] 17/10/2013 10:32

Nice inverted head and shoulders graph forming. Need to get above £2.40 and hold it before push on to £3 and beyond. Suspect we may see delayed trades later in the day.

[nod] 17/10/2013 10:05

Nod - 21 Jun 2013 - 20:29 - 1681 of 1738I suppose November is a big marketing campaign. I would have thought LMT would need to team up with a large medical device supplier to get exposure.Nod - 21 Jun 2013 - 20:37 - 1682 of 1738Such as Medtronic which is where our CEO used to work.Back on 22 march Canaccord had a target price of 325pToday saw Largest daily volume in three months.

[philo124] 17/10/2013 07:51

Pragmatic.

[skinny] 17/10/2013 07:31

It makes you wonder - maybe more advantageous to one party!

"The signing of this licensing agreement, the terms of which are advantageous to both parties,"

[rayrac] 17/10/2013 07:27

Yanks forcing their way in again. Why?

[skinny] 17/10/2013 07:05

London, UK and Irvine, CA, 17 October 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces it has entered into a mutually beneficial licensing agreement with Medtronic Inc.

Under the terms of the agreement, Lombard Medical has been granted a non-exclusive license by Medtronic to the US patent No. 6,306,141 ('141 or "Jervis" patent). Consequently, the Company will formally request a withdrawal of its petition to review the validity of the patent with the US Patent and Trademark Office (USPTO) regarding the '141 patent, (see 7 May 2013 Press Release). Other terms of the licensing agreement have not been disclosed.

Commenting on the licensing agreement, Simon Hubbert, Chief Executive of Lombard Medical, said: "The signing of this licensing agreement, the terms of which are advantageous to both parties, will allow Lombard Medical to focus our resources on the US launch of Aorfix™. While we do not believe that the Company infringes the '141 patent or any other Medtronic patent, we are keen to avoid potentially protracted and distracting IP discussions with a large and well-resourced company such as Medtronic."

Following receipt of US FDA approval earlier this year demand for our unique AAA stent graph continues to grow. The Aorfix physician training program has resulted in well over a hundred clinicians being trained and a number of Aorfix procedures have already been successfully completed in the US. The Company is also experiencing growing sales in Europe and anticipates regulatory approval for Aorfix in Japan in H1 2014. To meet this increasing demand the Company recently announced plans to expand its facilities in Didcot, Oxfordshire.


-Ends-

[nod] 11/10/2013 10:02

Write up in The Oxford TimesAnd the number involved in manufacturing the firm's Aorfix abdominal stent device is set to double in the next year following approval of the device by the US Food and Drug Administration.Human resources director Kate Forster said: "We are really proud of the business and want people to be involved in our success. It is a life-saving product and very satisfying to work on."The expansion looks likely to continue, with Aorfix set to receive regulatory approval in Japan early next year.About £300,000 is being spent on the Didcot facilities, including construction of a new "clean room", involving a special dust-free environment for manufacturing medical devices.Chief financial officer Ian Ardill added: "We are looking for people with the capacity to learn what we do."This area has a background in medical device manufacturing and we believe it is a good place to be with a lot of specialised people here."

[shorewalk] 08/10/2013 11:01

Should get update on sales in US before 2013 VEITH symposium in November. Looks like Sat 23rd will be main event. With luck will explain need for extra production capacity - wouldn't want to promote without being able to fulfil orders.

[nod] 07/10/2013 01:40

Highest share price in nearly six months. Some positive news would be good to keep the momentum going.

[rayrac] 03/10/2013 11:39

I would think £100,000 was a bit over the top. 50% of that perhaps! But at this stage who knows, the procedure has been carried out with the other inferior products in the market, so surely, the costs would be roughly the same?

Anyway, I'm quite pleased I'm here and not on the end of a procedure!

[nod] 03/10/2013 11:25

shorewalk, how do you know how many units were sold in any period? I looked for this number but couldn't find it.LMT has described how revenues have fluctuated due to "stocking/destocking". I'm guessing this relates to the need for some products to be on site or on demand for emergency situations.It would seem that revenues don't directly map to patient numbers. In the longer term they may but in the early stages of deployment probably not.It can take a long time for new products to get on the approved list of medical insurance companies, especially if it's a bit more expensive. Easier if it's a cheaper product. Similar situation to get on the approved list of the national health approval agency in each country. They decide what can be used in public hospitals and it is often not the best.If you are privately wealthy you can buy the best regardless - that's where the wealthy nations bit comes in.

[munkychunky] 03/10/2013 11:04

Personally I'm hopeful of good take up in NA. It's a superior product vs the competition and the only one that should be used in some cases. Really positive news about the expansion - still holding patiently! :)